SG11201811804QA - Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors - Google Patents
Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitorsInfo
- Publication number
- SG11201811804QA SG11201811804QA SG11201811804QA SG11201811804QA SG11201811804QA SG 11201811804Q A SG11201811804Q A SG 11201811804QA SG 11201811804Q A SG11201811804Q A SG 11201811804QA SG 11201811804Q A SG11201811804Q A SG 11201811804QA SG 11201811804Q A SG11201811804Q A SG 11201811804QA
- Authority
- SG
- Singapore
- Prior art keywords
- ingelheim
- international
- rhein
- gmbh
- ghrelin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16183047 | 2016-08-05 | ||
| PCT/EP2017/069274 WO2018024653A1 (en) | 2016-08-05 | 2017-07-31 | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811804QA true SG11201811804QA (en) | 2019-01-30 |
Family
ID=56609762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811804QA SG11201811804QA (en) | 2016-08-05 | 2017-07-31 | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US9994591B2 (ko) |
| EP (1) | EP3494120B1 (ko) |
| JP (1) | JP6651054B2 (ko) |
| KR (1) | KR102496075B1 (ko) |
| CN (1) | CN109843891B (ko) |
| AR (1) | AR109296A1 (ko) |
| AU (1) | AU2017307033B2 (ko) |
| CA (1) | CA3033058A1 (ko) |
| CL (1) | CL2019000274A1 (ko) |
| CO (1) | CO2019000601A2 (ko) |
| CY (1) | CY1124381T1 (ko) |
| DK (1) | DK3494120T3 (ko) |
| EA (1) | EA037277B1 (ko) |
| ES (1) | ES2874587T3 (ko) |
| HR (1) | HRP20210908T1 (ko) |
| HU (1) | HUE054928T2 (ko) |
| IL (1) | IL264506B (ko) |
| LT (1) | LT3494120T (ko) |
| MA (1) | MA45843B1 (ko) |
| MX (1) | MX2019001427A (ko) |
| MY (1) | MY197064A (ko) |
| PE (1) | PE20190414A1 (ko) |
| PH (1) | PH12019500254A1 (ko) |
| PL (1) | PL3494120T3 (ko) |
| PT (1) | PT3494120T (ko) |
| RS (1) | RS61937B1 (ko) |
| SA (1) | SA519401039B1 (ko) |
| SG (1) | SG11201811804QA (ko) |
| SI (1) | SI3494120T1 (ko) |
| TW (1) | TWI749042B (ko) |
| UA (1) | UA124267C2 (ko) |
| WO (1) | WO2018024653A1 (ko) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20210658A1 (es) | 2018-02-02 | 2021-03-31 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat) |
| CN111655699B (zh) * | 2018-02-02 | 2023-07-14 | 勃林格殷格翰国际有限公司 | 用作饥饿素o-酰基转移酶(goat)抑制剂的杂环基取代的噁二唑并吡啶衍生物 |
| US11136337B2 (en) | 2018-02-02 | 2021-10-05 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors |
| JOP20200190A1 (ar) * | 2018-02-02 | 2020-07-29 | Boehringer Ingelheim Int | مشتقات أوكسادايازولو بيريدين بها استبدال ببنزيل -، (بيريدين -3- يل) ميثيل - أو (بيريدين -4- يل) ميثيل كمثبطات جريلين o- أسيل ترانسفيراز (goat) |
| EP4153600B1 (en) | 2020-05-22 | 2024-08-07 | Boehringer Ingelheim International GmbH | Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
| JP2023526351A (ja) | 2020-05-22 | 2023-06-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルキル７－アミノ－５－メチル－［１，２，５］オキサジアゾロ［３，４－ｂ］ピリジンカルボキシレートの製造方法 |
| CN112014340A (zh) * | 2020-09-01 | 2020-12-01 | 广西玮美生物科技有限公司 | 非人灵长类动物胃饥饿素的检测方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2241496B1 (es) | 2004-04-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridina. |
| CL2007003580A1 (es) | 2006-12-11 | 2009-03-27 | Boehringer Ingelheim Int | Compuestos derivados de piridazina, antagonistas de mch; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos metabolicos y/o trastornos alimentarios como obesidad, bulimia, anorexia, hiperfagia, diabetes. |
| CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| US7994122B2 (en) | 2007-06-15 | 2011-08-09 | Zealand Pharma A/S | Glucagon analogues |
| JP5635529B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| CA2747112A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| KR101593406B1 (ko) | 2008-12-15 | 2016-02-12 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| KR20110126591A (ko) | 2008-12-15 | 2011-11-23 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| ES2537287T3 (es) | 2009-07-13 | 2015-06-05 | Zealand Pharma A/S | Análogos de glucagón acilados |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| MX2012014961A (es) | 2010-06-24 | 2013-02-26 | Zealand Pharma As | Analogos de glucagon. |
| AU2012357739A1 (en) | 2011-12-23 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Glucagon analogues |
| CA2864990C (en) * | 2012-02-24 | 2021-03-02 | Nobuyuki Takakura | Benzofuran and benzothiophene compounds for the inhibition of ghrelin o-acyltranferase (goat) |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA118034C2 (uk) | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази |
| US20170275249A1 (en) * | 2014-09-17 | 2017-09-28 | The Regents Of The University Of California | Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase |
| AR104672A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| AR104673A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| US11136337B2 (en) * | 2018-02-02 | 2021-10-05 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors |
| CN111655699B (zh) | 2018-02-02 | 2023-07-14 | 勃林格殷格翰国际有限公司 | 用作饥饿素o-酰基转移酶(goat)抑制剂的杂环基取代的噁二唑并吡啶衍生物 |
| PE20210658A1 (es) | 2018-02-02 | 2021-03-31 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat) |
| JOP20200190A1 (ar) | 2018-02-02 | 2020-07-29 | Boehringer Ingelheim Int | مشتقات أوكسادايازولو بيريدين بها استبدال ببنزيل -، (بيريدين -3- يل) ميثيل - أو (بيريدين -4- يل) ميثيل كمثبطات جريلين o- أسيل ترانسفيراز (goat) |
-
2017
- 2017-07-31 ES ES17743064T patent/ES2874587T3/es active Active
- 2017-07-31 UA UAA201901840A patent/UA124267C2/uk unknown
- 2017-07-31 US US15/664,119 patent/US9994591B2/en active Active
- 2017-07-31 HU HUE17743064A patent/HUE054928T2/hu unknown
- 2017-07-31 DK DK17743064.2T patent/DK3494120T3/da active
- 2017-07-31 CN CN201780047100.1A patent/CN109843891B/zh active Active
- 2017-07-31 KR KR1020197006448A patent/KR102496075B1/ko active IP Right Grant
- 2017-07-31 JP JP2019506164A patent/JP6651054B2/ja active Active
- 2017-07-31 SI SI201730770T patent/SI3494120T1/sl unknown
- 2017-07-31 PE PE2019000271A patent/PE20190414A1/es unknown
- 2017-07-31 PT PT177430642T patent/PT3494120T/pt unknown
- 2017-07-31 SG SG11201811804QA patent/SG11201811804QA/en unknown
- 2017-07-31 EA EA201990418A patent/EA037277B1/ru not_active IP Right Cessation
- 2017-07-31 LT LTEP17743064.2T patent/LT3494120T/lt unknown
- 2017-07-31 MY MYPI2018002719A patent/MY197064A/en unknown
- 2017-07-31 PL PL17743064T patent/PL3494120T3/pl unknown
- 2017-07-31 EP EP17743064.2A patent/EP3494120B1/en active Active
- 2017-07-31 MA MA45843A patent/MA45843B1/fr unknown
- 2017-07-31 AU AU2017307033A patent/AU2017307033B2/en active Active
- 2017-07-31 WO PCT/EP2017/069274 patent/WO2018024653A1/en unknown
- 2017-07-31 RS RS20210702A patent/RS61937B1/sr unknown
- 2017-07-31 CA CA3033058A patent/CA3033058A1/en active Pending
- 2017-07-31 MX MX2019001427A patent/MX2019001427A/es unknown
- 2017-08-04 AR ARP170102213A patent/AR109296A1/es unknown
- 2017-08-04 TW TW106126319A patent/TWI749042B/zh active
-
2018
- 2018-05-09 US US15/974,882 patent/US10308667B2/en not_active Ceased
-
2019
- 2019-01-22 CO CONC2019/0000601A patent/CO2019000601A2/es unknown
- 2019-01-28 IL IL264506A patent/IL264506B/en active IP Right Grant
- 2019-02-01 CL CL2019000274A patent/CL2019000274A1/es unknown
- 2019-02-05 SA SA519401039A patent/SA519401039B1/ar unknown
- 2019-02-06 PH PH12019500254A patent/PH12019500254A1/en unknown
-
2020
- 2020-10-14 US US17/069,940 patent/USRE49446E1/en active Active
-
2021
- 2021-06-08 HR HRP20210908TT patent/HRP20210908T1/hr unknown
- 2021-06-14 CY CY20211100525T patent/CY1124381T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811804QA (en) | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201809126RA (en) | Aromatic sulfonamide derivatives | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201408605UA (en) | Methods for biodegradable derivatization of cellulosic surfaces | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201805368YA (en) | Anthelmintic depsipeptide compounds | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201407988UA (en) | Process for improved opioid synthesis | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201803692PA (en) | Anti-5t4 antibodies and antibody-drug conjugates | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
| SG11201909735YA (en) | Therapeutic compounds and compositions, and methods of use thereof | |
| SG11201809560QA (en) | Enhancer of zeste homolog 2 inhibitors | |
| SG11201900336YA (en) | Radioligands for imaging the ido1 enzyme | |
| SG11201407303SA (en) | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders | |
| SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
| SG11201809086YA (en) | Treatment of liver, biliary tract and pancreatic disorders | |
| SG11201809687TA (en) | Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors |